It should be the discretion of individual physicians, not insurance companies or pharmacies, to substitute a branded biologic for a biosimilar, which goes back to putting the physician in the decision making process, not the non clinical analyzers. While the search for "cheap" continues...
Posted to
The Medical Quack .... by Barbara Duck
on 08-14-2008
Filed under: Medically Related, Technology, My Commentaries, DNA, Genomics, Biotech, Research, Congress, Pharmaceuticals, Biosimilars
" However, the NCI director did not hold out much hope in the upcoming presidential elections, saying the slate of available candidates was "a disappointment." ....and yes I can agree with this statement...nothing personal against any candidate or their staff....but as long as we continue...